A Personal Journey that Became a Clinical Mission
Born three months premature and weighing less than two pounds, I was given little chance of survival. While I defied the odds, the most enduring complication was not a predicted disability but a devastating case of steroid-dependent childhood asthma that resulted in yearly hospitalizations for pneumonia. By the age of sixteen, I had cycled through an exhaustive list of conventional therapies such as oral prednisone, rescue inhalers, nebulized budesonide and albuterol, as well as combination inhalers like Advair, with only limited and temporary relief.
Years later, after founding Juventix Regenerative Medical, I discovered emerging literature on nebulized lidocaine for asthma management. Inspired by this, I first trialed buffered lidocaine, then progressed to a more therapeutic and autologous approach: Platelet-Rich Plasma (PRP). Using the Juventix 12ML2 PRP kit, I prepared and nebulized PRP twice daily. The results were transformative: within weeks I discontinued all medications, including my rescue inhaler, and have remained symptom-free for more than 8-years.
This deeply personal experience became the catalyst for my clinical exploration into the broader potential of PRP. Today, that protocol, now refined and standardized, is being considered for a range of chronic pulmonary disorders, including sarcoidosis, COPD, bronchitis, asthma, and bronchopleural fistulas, where its regenerative, anti-inflammatory, and immunomodulatory properties may offer meaningful, non-pharmacologic therapeutic alternatives for a large patient population.
Pathophysiology Meets Biologic Intelligence
Sarcoidosis is a systemic granulomatous disease, often affecting the lungs. While its exact cause remains unknown, it is marked by immune dysregulation, inflammatory infiltration, and fibrotic remodeling of alveolar tissue. Mainstream treatment often relies on chronic corticosteroids or immunosuppressants, which can carry significant long-term risks.
What makes PRP relevant to this condition is its inherent anti-inflammatory, immunomodulatory, and regenerative capacity:
- TGF-β and PDGF-BB in PRP may help downregulate the fibrotic activity seen in pulmonary sarcoidosis.
- VEGF contributes to endothelial repair and improved capillary exchange, possibly counteracting pulmonary hypertension.
- IL-1β inhibition may modulate the excessive immune signaling involved in granuloma formation.
- Autologous bio-compatibility eliminates rejection risk and offers a safer long-term profile compared to synthetic biologics or corticosteroids.
A Clinical Case: Nebulized PRP for Sarcoidosis
Chaz Moore, PA-C of Cedar Mental Health and Wellness Group, reported a compelling patient case using Juventix PRP for pulmonary sarcoidosis:
“As an update for my patient who completed nebulized PRP therapy for sarcoidosis, he reported improved oxygenation and no longer required oxygen continuously throughout the night. He also stated he tolerated higher elevations better, with oxygen saturation levels consistently above 92%. Additionally, he experienced a complete absence of his typical springtime allergies and bronchitis, conditions that plagued him annually. While we did not expect these added benefits, he was grateful for the overall symptom reduction and prevention of his usual seasonal respiratory complications.”
This case not only reinforces PRP’s anti-inflammatory properties but also highlights its potential for immune modulation and epithelial repair in complex autoimmune pulmonary conditions like sarcoidosis.
Science-Backed Evidence Supporting PRP Therapy
Research has shown PRP to be rich in bioactive factors like VEGF, PDGF-BB, TGF-β, and IL-1β inhibitors—agents that modulate inflammation, enhance vascular integrity, and stimulate tissue regeneration.
Knight & Kacker (2023) in Cureus reported measurable improvements in pulmonary function and reduced disease progression in patients with chronic respiratory conditions receiving PRP.
Ye et al. (2024) showed that PRP sealed bronchopleural fistulas with 87.6% success a testament to its wound-healing and epithelial-repair potential.
Roussey et al. (2007) reported that PRP increased VEGF and TGF-beta expression in alveolar tissues, improving oxygenation efficiency and reducing dead space.
Lefrançais et al. (2017) demonstrated that the lungs are not merely passive gas-exchange organs, but instead serve as an active site of platelet biogenesis and immune regulation. This discovery highlights the lungs’ role in producing circulating platelets and housing hematopoietic progenitor cells, thereby validating the targeted application of autologous platelet-derived biologics directly to pulmonary tissue for regenerative and immunomodulatory purposes.
Together, these findings provide a rational, mechanistic foundation for the use of PRP in conditions such as sarcoidosis, COPD, bronchitis, and asthma, supporting its potential as a non-pharmacologic, autologous treatment option for a wide range of pulmonary compromise through localized regenerative effects.
Other Respiratory Conditions that May Benefit
- Chronic Obstructive Pulmonary Disease (COPD)
- Emphysema
- Recurrent Bronchitis
- Asthma with steroid intolerance
- Post-viral persistent symptoms
- Bronchopleural Fistulas
Why Juventix PRP Leads the Way
At Juventix Regenerative Medical, our PRP kits are FDA-cleared, cost-efficient, and clinically engineered for optimal platelet recovery. They simplify preparation while producing reliable platelet concentrations that support targeted use – whether in orthopedics, aesthetics, or respiratory care.
Try Juventix PRP For Yourself
For a limited time, Juventix is offering a $20 sample kit for licensed practitioners.
Email hello@juventix.com with subject “SAMPLE”
Visit https://juventix.com/sample-page/
Explore the Future of Regenerative Care
To schedule a FREE introductory webinar and learn how to implement PRP therapy in your practice to deliver real regenerative outcomes:
Visit www.juventix.com or call (866) 693-4777
About the Author
Lance Liberti, MBA, is the founder and president of Juventix Regenerative Medical and Integrative Practice Solutions. With over 20 years of experience in medical device marketing, clinical training, product development, and practice management, he has helped thousands of providers transform their clinics with regenerative and biologic technologies. Connect: https://www.linkedin.com/in/lanceliberti
References
- Knight, A., & Kacker, S. (2023). Platelet-Rich Plasma Treatment for Chronic Respiratory Disease. Cureus, 15(1), e33265. https://pubmed.ncbi.nlm.nih.gov/36741673/
- Ye, Y., et al. (2024). Efficacy and Safety of Platelet-Rich Plasma on Bronchopleural Fistula. Archivos de Bronconeumología. https://pubmed.ncbi.nlm.nih.gov/39214770/
- Lefrançais, E., et al. (2017). The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature, 544(7648), 105-109. https://pubmed.ncbi.nlm.nih.gov/28329764/
- Roussey Y., et al. (2007). Growth Factor Release from PRP in Pulmonary Therapy. Clinical Oral Implants Research.
- Mohamed, R., et al. (2014). Nebulized Lidocaine in Acute Asthma. BMC Pulmonary Medicine, 14(94). https://pmc.ncbi.nlm.nih.gov/articles/PMC4129744/
- Louie, S., et al. (2004). Treatment of Asthma with Nebulized Lidocaine. Chest, 125(5), 1591–1595. https://pubmed.ncbi.nlm.nih.gov/15131566/
Legal Disclaimer
This article is intended for informational purposes only and does not constitute medical advice. PRP has not been approved by the FDA specifically for the treatment of sarcoidosis or respiratory disease. Healthcare providers should use clinical judgment and regulatory guidance when implementing therapies. Juventix Regenerative Medical assumes no liability for outcomes based on off-label product use.
